$0.03
+0.00 (+9.48%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BPTH is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional
Held by 0 tracked-famous managers · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AMLNCT02781883Assessment of efficacy in untreated AML subjects by bone marrow aspirate or biopsyNon-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: BP1001 in combination with Ventoclax plus decitabine, BP1001 plus decitabine | Acute Myeloid Leukemia (AML) | 108 | Dec 2027 | ≤ 499 d | 2025-03-07 |
| BP1001-A in Patients With Advanced or Recurrent Solid TumorsNCT04196257Identify Dose Limiting Toxicity (DLT) of BP1001-ANon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide), BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel | Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Endometrial Cancer, Peritoneal Cancer, Solid Tumor | 50 | Jul 2027 | ≤ 346 d | 2025-03-07 |
| A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)NCT05190471Identify Dose Limiting Toxicity (DLT) of BP1002Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide, Decitabine (in combination with BP1002) | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | 48 | Mar 2027 | ≤ 224 d | 2025-03-10 |
| A Clinical Trial of BP1002 in Patients With Advanced Lymphoid MalignanciesNCT04072458Identify Dose Limiting Toxicity (DLT) of BP1002Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: L-Bcl-2 antisense oligonucleotide | Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Marginal Zone Lymphoma, Hodgkin Lymphoma, Waldenstrom Macroglobulinemia, DLBCL | 30 | Apr 2025 | — | 2025-02-24 |
| Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDSNCT02923986Dose Limiting Toxicity of BP1001 using non-hematologic and hematologic parameters per NCI CTCAE criteriaNon-randomized · Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: No enrollment | Drug: BP1001 (varying dose), BP1001 (fixed dose), Dasatinib | Chronic Myelogenous Leukemia, Ph1-Positive, Acute Myeloid Leukemia, Myelodysplastic Syndrome | 0 | 2020-05-27actual | — | 2020-05-28 |
| Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDSNCT01159028Safety of BP1001Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BP1001, BP1001 in combination with LDAC | Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Ph1 Positive CML | 60 | 2017-03-30actual | — | 2020-05-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19